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Abstract  
Introduction: Ketamine is a commonly used medicine for reducing pain and stress in patients, including 
children in emergency department (ED). The intravenous (IV) injection of ketamine is gold standard though 
difficult in children, but other routes are also possible. 
Objective: This study was conducted to compare the effects of the submucosal at different doses versus IV 
injections of ketamine on sedation with proper consciousness in children candidates for diagnostic-
therapeutic procedures in ED. 
Methods: This randomized clinical trial was conducted with 4 groups; groups 1, 2 and 3 respectively received 
4, 3 and 2 mg/kg of submucosal ketamine and group four 1.5 mg/kg of IV ketamine. Eligible subjects selected 
from 46 patients of children’s age as the candidates for subcutaneous wound healing were randomly assigned 
to the four groups and followed up 5, 10, 15 and 30 minutes after the injection. The Ramsay score was obtained 
by measuring the heart rate, the breathing rate, the time to start affecting and duration of the effect. The data 
were ultimately analyzed in SPSS and Excel.  
Results: The baseline data were matched and confounding variables eliminated included age, gender, weight 
and hemodynamics. Compared to other doses of submucosal ketamine, 4 mg/kg was found to exert its effect 
the fastest (4.08±1.01 minutes) (p<0.05) and for the longest duration (23.09±1.12 minutes) (p<0.05). The 
Ramsay score in groups 1 and 4, i.e. 5.9, was significantly higher than that in groups 2 and 3 (p<0.05). 
Conclusions: The results showed that 4 mg/kg and 3 mg/kg of submucosal ketamine are appropriate 
alternatives to IV ketamine. Although the time to start affecting was shorter in the intravenous group compared 
to in the other groups, the duration of the effect was the longest with 4 mg/kg of submucosal ketamine. Surgeon 
satisfaction scores were found to be very good and not significantly different between groups 1, 2 and 4. 
Vomiting was also prevalent with no significant differences between the four groups. 
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INTRODUCTION
Taking care of patients who need emergency 
services is an important duty in emergency 
department (ED), especially when they need 
diagnostic-therapeutic procedures (1, 2). 
Analgesics and sedatives are required in EDs to 
prevent the potential pain and stress caused by 
diagnostic and therapeutic procedures (3-5). 
Ketamine is a popular non-barbiturate dissociative 
agent that induces rapid and profound sedation, 
analgesia and amnesia (6-8). In addition to 
anesthetic effects, analgesia is induced by ketamine 
at doses as low as 0.1-0.3 mg/kg and below the 
anesthetic doses to relieve acute and chronic pains 
(9-11). Ketamine is now commonly administrated 
intramuscularly or intravenously for sedation in 
pediatric EDs. The advantages of the intramuscular 
administration include no needs for venipuncture 
and those of the intravenous (IV) administration 
include faster effects and recovery (12). Recently, 
some recommend that the submucosal 
administration to offer both these advantages, and 
preferred the submucosal to intramuscular 
injection (13). For as much as the comparison of IV 
and submucosal injection effects have not been 
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studied in the case of emergency procedures and 
surgeon satisfaction until now and injection in the 
buccal region due to extensive vascular system and 
high absorption and localized anesthetic by local 
gel is a good way to calm the children, whom should 
tolerate a very painful and stressful moments for 
their proper venipuncture. The present study was 
therefore conducted to investigate the effects of the 
submucosal at different doses versus IV injections 
of ketamine on sedation with proper consciousness 
in children as candidates for diagnostic-
therapeutic procedures in the ED.  
Methods 
Study design and setting  
This randomized clinical trial was conducted in the 
EDs of Al-Zahra and Kashani hospitals, Isfahan, 
Iran. The study was performed after receiving the 
approval of the Research Ethics Committee of 
Isfahan University of Medical Sciences (code: 
IR.MUI.REC.1396.3.110). The investigators were 
adhered to Declaration of Helsinki Principles 
throughout the study. Signed informed consent 
were received from the patients’ parents before 
starting the intervention. 
Study population 
The inclusion criteria comprised an age of 2-8 years 
candidates for diagnostic-therapeutic procedures 
in the ED. The exclusion criteria consisted of 
allergies to ketamine, psychophysical disabilities, 
immune system disorders, other urgent needs for 
IV injections in group 4, contraindications for 
ketamine administration such as hypertension and 
recent seizures, history of thyroid diseases, 
glaucoma, active upper respiratory tract or lung 
infections, hydrocephalus, central nervous system 
masses, porphyria and heart diseases such as 
angina pectoris, history of airway disorders and 
tracheal stenosis, major procedures causing 
posterior nasopharyngeal inflammation and sever 
damage to the head, any breathing and 
hemodynamic disorders requiring support and 
emergency interventions.  
The sample size was calculated as 42 in each group 
using the mean difference formula for the Ramsay 
score (mean difference=0.8 and standard 
deviation=1.3) at a confidence interval of 0.95 and 
a power of 0.8. Sampling was performed via 
convenience method. 
Intervention and data gathering 
The eligible patients were randomly assigned to 
the 4 groups using a random-allocation software 
package. Groups 1, 2 and 3 respectively received 4, 
3 and 2 mg/kg of submucosal ketamine and group 
four 1.5 mg/kg of IV ketamine. Blinding was 
impossible in the four groups, although double 
blinding was performed in terms of ketamine dose 
in groups 1-3. Ketamine hydrochloride made by 
Rotexmedica company in Germany was injected in 
the present study with a Gaj insulin syringe 28. 
Baseline variables included age, gender and weight. 
Surgeon satisfaction scores comprised 0: very bad, 
1: bad, 2: moderate, 3: good and 4: very good. The 
Ramsay sedation scale scores included 1 meaning 
the patient is anxious, agitated and restless, 2 
meaning the patient is cooperative, oriented and 
tranquil, 3 meaning the patient is responsive to 
commands only, 4 meaning the patient quickly 
responds to light glabellar taps or loud auditory 
stimuli, 5 meaning the patient slowly responds to 
light glabellar taps or loud auditory stimuli and 6 
meaning the patient does not respond to light 
glabellar taps or loud auditory stimuli (1, 14). 
The time during which ketamine begins to exert its 
effects was the interval between injecting ketamine 
and beginning to disobey the commands by the 
patient. The effect duration was also the interval 
between beginning to disobey and to obey again. 
Homodynamic parameters, including the heart 
rate, the breathing rate and oxygen saturation, 
were measured before and 5, 10, 15 and 30 
minutes after the injection. 
Statistical analysis 
The data were expressed as frequency, relative 
frequency and mean values. The Chi-squared test 
and Fisher’s exact test were used to assess 
differences in the distribution of the categorical 
variables such as gender and vomiting among the 
study groups. ANOVA was performed to assess 
mean differences in the numerical variables among 
the study groups. Moreover, repeated measures 
ANOVA was used to assess mean differences in the 
numerical variables between the five time points. 
The Bonferroni method was used for the pairwise 
comparison of the independent groups and the 
Shapiro-Wilk test to investigate the normality 
distribution of the data. Level of statistical 
significance was set at P<0.05. The statistical 
analyses were performed in SPSS-25 (IBM Corp., 
Armonk, N.Y., USA). 
RESULTS 
According to figure 1, this study analyzed the data 
of 173 patients in four groups. Submucosal 
ketamine was administered at 4 mg/kg in 35 
patients, at 3 mg/kg in 43 and at 2 mg/kg in 47 and 
intravenous ketamine was administered at 1.5 
mg/kg in 48 patients. The mean age of the patients 
obtained as 3.3 years was not significantly different 
between the four groups (p=0.988). Approximately 
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50% of the patients in each group were male and 
no significant differences were observed in gender 
distribution (p=0.916) and weight (p=0.408) 
between the study groups (table 1).  
Statistically-significant differences were observed 
between the groups in terms of the time to start 
affecting in minutes (p<0.001). The intravenous 
administration with the dose of 1.5 mg/kg resulted 
in the minimum time to affect after the injection 
(1.13±0.35 minutes), which was significantly 
different from that in the three submucosal groups. 
The times to start affecting obtained as 4.09 
minutes with 4 mg/kg of submucosal ketamine and 
4.05 minutes with 3 mg/kg were shorter than that 
with 2 mg/kg (4.77 minutes), suggesting 
statistically-significant differences (p<0.001); the 
difference between the submucosal injection at 4 
and 3 mg/kg was, however, insignificant (p=1.0) 
and between 4 and 2 mg/kg was marginally 
significant (p=0.051) (table 1). 
The longest (23.09±1.12 minutes) and shortest 
(14.15±1.23 minutes) durations of the effect were 
respectively associated with 4 and 2 mg/kg of 
submucosal ketamine. The duration of the effect 
obtained as 17.94±1.26 minutes in the intravenous 
group was shorter than that of 2 mg/kg of 
submucosal ketamine and lower than that of 3 
mg/kg of submucosal ketamine. Table 1 shows 
significant differences in the mean duration of the 
effect for all the pairwise comparisons among the 
four study groups (p<0.001).  
The mean surgeon satisfaction score obtained as 
2.02 at 2 mg/kg of submucosal ketamine was lower 
than that in the other three groups, which was over 
3.0. The difference in the mean satisfaction score 
was statistically significant between the 2 mg/kg  
Figure 1: The study flowchart 
 
Table 1: Comparing demographic information and the intervention effect among the four groups 
 
Submucosal ketamine 
Intravenous 
ketamine 
P 
Significant 
difference*  4 mg/kg  
(n=35) 
3 mg/kg  
(n=43) 
2 mg/kg 
(n=47) 
1.5 mg/kg 
(n=48) 
Age; mean±SD 3.37±0.71 3.39±0.94 3.34±1.04 3.33±0.9 0.988 - 
Gender; n(%)     
 
0.916 
- Male 20(57.1) 24(55.8) 25(53.2) 24(50.0) 
Female 15(42.9) 19(44.2) 22(46.8) 24(50.0) 
Weight; mean±SD (Kg) 13.42±2.06 13.69±1.8 13.95±1.83 13.33±2.0 0.408 - 
Mean time to start the effect; 
mean±SD (min) 
4.09±1.01 4.05±1.17 4.77±1.54 1.29±0.65 <0.001 1,4; 2,3; 2,4; 3,4 
Mean duration of the effect; 
mean±SD (min) 
23.09±1.12 20.35±1.25 14.15±1.23 17.94±1.26 <0.001 
All the pairwise 
comparisons 
Surgeon satisfaction score; 
mean±SD 
3.80±0.53 3.84±0.48 2.02±1.01 3.83±0.48 <0.001 1,3; 2,3; 3,4 
Ramsay score; mean±SD 5.8±0.2 4.93±0.23 4.01±0.18 5.91±0.21 <0.001 1.2; 1.3; 2.3; 2,4; 3,4 
Vomiting; n(%) 5 (14.28) 6 (13.95) 6 (13.04) 5 (9.5) 0.869 - 
*Pairwise comparison based on the Bonferroni method 
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Figure 2: Breathing rate in the four groups at different time points 
 
 
Figure 3: The heart rate in the four groups at different time points 
 
Figure 4: The heart rate in the four groups at different time points 
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submucosal group and the other three groups 
(p<0.001) (table 1).  
The Ramsay scores obtained as 5.91±0.21 in group 
4 and 5.80±0.2 in group 1 were higher than the 
score in the other two submucosal groups. Pairwise 
comparison showed a significant difference 
between every two groups, except for between 
groups 1 and 4 (table 1).  
The mean satisfaction score obtained as 2.02 at the 
lowest submucosal dose (2 mg/kg) was lower than 
the mean satisfaction score of over 3.0 in the other 
three groups, suggesting a statistically-significant 
difference (p<0.001) (table 1). 
Vomiting in the intravenous group obtained as 
9.5% was lower than 13.0%-14.3% in the other 
three groups, suggesting a statistically-
insignificant difference among the four groups 
(p=869) (table 1).  
The breathing rate was significantly different 
among the five time points in all the study groups 
(p<0.001). No statistically-significant differences 
were observed in the breathing rate of 
approximately 32.0 observed in the four groups 
before the administration (p=0.878). The 
breathing rate was minimized at 23.0±1.08 in 
group 1 and 27.11±1.40 in group 3 five minutes 
after the injection (p<0.001). Also, the breathing 
rate in other time interval was lowest and highest 
in SI 4mg/kg and SI 2mg/kg group, respectively. 
Pairwise comparison showed statistically-
significant differences in the breathing rate only 
between groups 3 (31.17±1.11) and 4 (30.27±1.09) 
thirty minutes after the intervention (p=0.005). 
Table 2 presents the results of the pairwise 
comparison between the four groups at all the time 
points. According to figure 2, the increase observed 
at this rate at minute 30 was insignificantly lower 
than the rate before the administration.  
Figure 3 shows variations in the heart rate, 
suggesting no significant differences between the 
study groups before the intervention (p=0.572). 
The heart rate was maximized five minutes after 
the intervention in all the four groups and the 
maximum was the lowest (92.44±2.34) and highest 
(94.02±1.34) in groups 2 and 3, respectively 
(p<0.001). The heart rate was gradually decreased 
after minute 5 and minimized at minute 30 in 
groups 1 (87.09±1.50) and 4 (86.63±1.02) 
(p<0.001) and difference between other pairwise 
was significant (table 2).  
According to figure 4, the critical reduction in 
oxygen saturation within the first 5 minutes in 
group 1 (96.29±0.79) required support for the 
patients. Oxygen levels increased after minute 5 
with the reduction in the effect of the medicine and 
reached normal levels at minute 30. The difference 
in the breathing rate was significant between every 
two groups at the five time points (p<0.001). Table 
Table 2: Breathing rate, heart rate and oxygen rate at different time points and pairwise comparison among the study groups 
Group 
Time Point  
Before 
intervention 
5 min after 
intervention 
10 min after 
intervention 
15 min after 
intervention 
30 min after 
intervention 
P 
Respiratory rate; mean±SD (/min)  
1 
2 
3 
4 
32.20±1.11 
32.16±1.0 
32.34±1.15 
32.27±1.12 
23.0±1.08 
24.07±0.83 
27.11±1.40 
23.04±1.07 
23.14±1.03 
25.67±1.19 
27.43±1.36 
24.44±0.97 
25.14±0.88 
25.77±1.0 
29.60±1.47 
26.65±0.96 
30.60±1.38 
30.58±1.31 
31.17±1.11 
30.27±1.09 
<0.001 
<0.001 
<0.001 
<0.001 
P 0.878 <0.001 <0.001 <0.001 0.005  
Significant 
difference* 
- 1,2; 1,3; 2,3; 2,4; 3,4 
All pairwise 
comparisons 1,3; 1,4; 2,3; 2,4; 3,4 3,4  
 Heart rate; mean±SD (/min)  
1 
2 
3 
4 
85.69±1.37 
85.47±2.02 
85.45±1.90 
85.15±1.61 
93.54±2.09 
92.44±2.34 
94.02±1.34 
93.27±1.20 
93.06±1.95 
91.74±2.79 
93.04±1.38 
93.06±1.06 
90.09±1.69 
91.21±2.51 
89.85±1.30 
92.02±1.08 
87.09±1.50 
90.09±2.42 
88.83±1.22 
86.63±1.02 
<0.001 
<0.001 
<0.001 
<0.001 
P 0.572 0.001 0.002 <0.001 <0.001  
Significant 
difference* 
- 1,2; 2,3 1,2; 2,3; 2,4 1,2; 1,4; 2,3; 3,4 1,2; 1,3; 2,3; 2,4; 3,4  
 Oxygen saturation; mean±SD (%)  
1 
2 
3 
4 
97.0±0.80 
96.91±0.89 
96.89±0.84 
96.46±0.90 
96.29±0.79 
97.09±1.06 
97.11±0.87 
97.90±0.52 
96.86±0.77 
96.23±0.68 
97.04±0.93 
96.96±0.87 
98.77±0.43 
96.51±0.67 
96.30±0.66 
98.17±1.10 
97.23±0.94 
98.58±0.73 
98.15±1.08 
96.67±1.06 
<0.001 
<0.001 
<0.001 
<0.001 
P 0.016 <0.001 <0.001 <0.001 <0.001  
Significant 
difference* 
1,4 1,2; 1,3; 1,4; 2,4; 3,4 1,2; 2,3; 2,4 1,2; 1,3; 1,4; 2,4; 3,4 1,2; 1,3; 2,4; 3,4  
*Pairwise comparison based on the Bonferroni method 
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2 presents the results of pairwise comparison 
between the four groups at all the time points 
DISCUSSION 
This study was conducted to compare the effects of 
2, 3 and 4 mg/kg of submucosal ketamine and 1.5 
mg/kg of intravenous ketamine. Ketamine can be 
administered in intravenous, intramuscular, 
intrabuccal and subcutaneous manners. Although 
the advantages and disadvantages of these 
administration methods have been addressed in 
literature, there is no consensus among clinicians 
about the superiority of any of these methods (15). 
No significant differences observed between the 
study groups in the baseline characteristics, 
including gender, age and weight, suggested the 
absence of confounding variables. The results of 
this study showed the shortest time to start 
affecting in group 4 with a mean difference of 
approximately 2.5 minutes respectively followed 
by group 2 (4.05 minutes) and group 1 (4.09 
minutes), suggesting a significant difference from 
that in group 3. The present study also found the 
effect duration in group 1 to be the longest and at 
least five minutes longer than in group 4. The 
longest duration of the effect was also reported for 
intramuscular ketamine compared to intravenous 
ketamine. Comparing the effects of intravenous 
ketamine with those of intramuscular ketamine in 
children admitted to emergency departments 
showed a significantly longer mean duration of 
sedation in the intramuscular group than in the 
intravenous group (14). Similarly, the mean length 
of time between receiving the sedative and 
awakening was significantly shorter in the 
intravenous ketamine group (36.2±0.5 minutes) 
compared to in the intramuscular ketamine group 
(56.5±0.6 minutes) (14).  A randomized clinical 
trial recruiting 120 patients found a time to start 
affecting of 1.7±1.1 minutes with 1.5 mg/kg of 
intravenous ketamine and 8.6±3.1 minutes with 4 
mg/kg of intramuscular ketamine and a mean 
duration of optimal sedation of 20.6±12.0 minutes 
in the intravenous group and 37.2±11.8 minutes in 
the intramuscular group (16). Investigating 
pediatric patients receiving ketamine for 
orthopedic procedures also found duration of 
sedation to be significantly longer with 4 mg/kg of 
intramuscular ketamine (median: 129 minutes) 
compared to with 1 mg/kg of intravenous 
ketamine (median: 80 minutes) (14). 
Momeni et al. (14) found intravenous ketamine 
more desirable while reporting a longer duration of 
sedation in the intramuscular ketamine group 
compared to in the intravenous ketamine group. 
The present study found 4 mg/kg of submucosal 
ketamine to cause a mean duration of the effect of 
23.09±1.12 minutes, as opposed to the 
significantly-longer duration of 45 minutes 
reported for intramuscular ketamine. Submucosal 
administration of ketamine therefore appears 
more appropriate than the intramuscular and 
intravenous administration.  
Majidi et al. (13) found the time to start affecting to 
be shorter for intrabuccal injection compared to for 
intramuscular injection. They reported fewer 
complications in the intrabuccal group than in the 
intramuscular group, which is consistent with the 
present findings, which recommended the 
submucosal administration rather than the 
intravenous administration. According to Majidi 
Nejad et al., although intravenous ondansetron can 
reduce the side effects (17), the problems of the 
intravenous administration of ondansetron still 
persist, which suggests the use of ondansetron 
intramuscularly or in other ways.  
The present study found the surgeon satisfaction 
score (very good) to be equal in groups 1 and 4. 
Insignificant differences in this score were also 
reported between different methods of 
administering ketamine in literature; for instance, 
no significant differences were reported in the 
satisfaction score between the intramuscular and 
intravenous methods of administering ketamine 
(16). In contrast, Majidi et al. reported a 
significantly-lower median surgeon satisfaction 
score in the intramuscular group compared to in 
the intrabuccal group (13). 
The present study found the prevalence of 
vomiting to range from 9.5% in group 4 to 14.28% 
in group 1, suggesting insignificant differences 
between the four groups. Research suggests a very 
high incidence of nausea in children receiving 
ketamine and that nausea and vomiting are the 
only side effects (16, 17). Similarly, the incidence of 
vomiting was obtained as 17.8% in the 
intramuscular ketamine-placebo group and 26.7% 
in the intravenous ketamine-placebo group (17). 
Roback et al. also reported a higher prevalence of 
vomiting with intramuscular ketamine (26.3%) 
compared to with intravenous ketamine (11.9%) 
(16).   
The analgesic effect of submucosal ketamine (4 
mg/kg) was found to resemble that of intravenous 
ketamine and higher than that in groups 2 and 3 in 
terms of the Ramsay score. In contrast to 
intravenous ketamine, submucosal ketamine 
resulted in a higher reduction in the breathing rate 
in groups 1-3. Submucosal ketamine should be 
therefore administered more cautiously and 
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carefully while monitoring patients, especially in 
the first 5 minutes. Variations in the heart rate 
were the same in all the four groups. The highest 
increase in this vital sign was observed in the first 
five minutes, especially in group 3 by 94 bpm. The 
heart rate was, however, almost the same in groups 
1 and 4. The fall in the breathing rate was followed 
by a decrease in oxygen saturation in the first 5 
minutes in group 1. In other words, the patients 
receiving 4 mg/kg of submucosal ketamine 
required respiratory support. Many studies have 
compared intravenous ketamine with 
intramuscular ketamine. Submucosal ketamine, 
however, offers more advantages and causes fewer 
side effects than those of intravenous and 
intramuscular ketamine. The present research 
conducted to compare these methods with 
different doses to select the best one, especially for 
children in emergency departments 
Limitations 
As in the case of any studies, the present research 
suffered limitations; for instance, vomiting was the 
only investigated side effect with a low prevalence 
that resulted in a low statistical power in assessing 
differences between the groups. It is therefore 
recommended that future studies be conducted 
with larger samples and address other side effects. 
Given the failure of this study to investigate the 
contribution of confounding variables to the effect 
of the medicine in different groups, future studies 
are required to address these factors. Another 
limitation of this study was to evaluate satisfaction 
in the physicians using a single question. Future 
studies are therefore required to explore different 
effective dimensions in the satisfaction with a 
higher number of questions and in more detail. 
CONCLUSIONS 
The present findings suggested a significantly-
shorter time to start affecting in emergency unit 
procedures in the intravenous group compared to 
in the other submucosal groups. The duration of 
the effect was also found to be significantly longer 
using 4 mg/kg of submucosal ketamine compared 
to using intravenous ketamine. The surgeon 
satisfaction score was significantly lower in group 
3 compared to in the insignificantly-different 
groups of 1, 2 and 4. Complications such as 
vomiting was prevalent with no significant 
differences between the submucosal groups and 
the intravenous group. The present study 
pioneered the investigation of intravenous and 
submucosal ketamine at different doses to select 
the best method and dose. Moreover, 4 mg/kg and 
3 mg/kg of submucosal ketamine were found to 
constitute appropriate alternatives to intravenous 
ketamine. Submucosal administration is therefore 
recommended and preferred over the intravenous 
administration. 
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